Pharma Stocks

Thus far in the calendar year 2024 (CY24), the market price of Neuland Laboratories has zoomed 216%, Piramal Pharma (88%), Divi's Labs (53%) and Jubilant Pharmova (52%)

Biocon's Bengaluru API facility was inspected between September 23 to September 27, 2024

The fall in Granules India share price came after the company announced that United States Food and Drug Administration (USFDA) has classified the inspection of Gagillapur unit as OAI

The uptick in Gland Pharma share came after the company said that it has received approval from the United States Food and Drug Administration (US FDA) for Latanoprost Ophthalmic Solution

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

The management anticipates stronger performance in the coming quarters due to the company's upcoming new launches, the onset of the winter season and scaling up of the TEVA facility.

The collaboration and licencing agreement is set to span three to five years and focuses on the joint development of specific products within the respiratory therapeutic area, Aurobindo Pharma said

In Q2 the company delivered impressive 31.8% YoY revenue growth, of which 23.0% was organic, driven primarily by volume, with contributions coming from both its existing and newly launched centres.

In two days, the stock price of Akums Drugs has declined 19% to Rs 645.30 and fallen below its issue price of Rs 679 per share.

Till 12:35 pm; a combined 32.3 million shares representing 2.43 per cent of total equity of PPL changed hands on the NSE and BSE.

Despite increased EBITDA loss at Cenexi, the overall consolidated EBITDA margin was better-than-expected at 21.1%, led by better segmental mix and controlled operational cost for the quarter.

Over the long term, the management remains committed to achieving the company's financial goals of $2 billion revenue with 25 per cent EBITDA margin and 1x net debt / EBITDA by FY30.

Wockhardt shares surged 5% to Rs 1,212.55, its highest level since February 2016 and has zoomed 157% thus far in the calendar year 2024.

The uptick in Jagsonpal Pharma share price came after the company announced that its board of directors will meet on October 23 to consider Q2 and H1FY25 results and proposal for stock-split

Wockhardt is also developing additional insulin analogs and GLP-1 agonists to provide advanced diabetes care solutions

Lyka Labs shares rose as the company announced that it has received the CDSCO approval for manufacturing & marketing of of Pregabalin Gel 8% w/w for use in patients with Diabetic Neuropathic Pain.

Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)

Shilpa Medicare share price surged after the company said that its arm, Shilpa Pharma Lifesciences, has received certificate of suitability (CEP) from EDQM for API, Desmopressin

Alembic Pharma share price surged after the United States Food and Drug Administration (USFDA) gave final approval for Lamotrigine ExtendedRelease Tablets USP, 200 mg, 250 mg, and 300 mg.

Alembic Pharma share price surged after the USFDA issued establishment inspection report (EIR) for the inspection carried out at the company's Oral Solid Formulation Facility (F-I).